Mode of Administration: Subcutaneous Injection

2 trials

Sponsors

Intas Pharmaceuticals Ltd, LONG GROVE PHARMACEUTICALS LLC

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Phase 1

A pharmacokinetic and pharmacodynamic study of pegfilgrastim (test drug) with Neulasta of Amgen (reference drug, EU Licensed Product) in normal adult human subjects under fasting conditions.

Active, not recruitingCTRI/2016/07/007096

Intas Pharmaceuticals Ltd

Target: 344Updated: 2021-11-24

Unknown Phase

A Study of ZOLADEX 3.6 mg in women with advanced Breast Cancer

Active, not recruitingCTRI/2019/03/018338

LONG GROVE PHARMACEUTICALS LLCHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site

Target: 20Updated: 2021-11-24